• About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Media Library
    • Philogen in the news
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)
Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Philogen in the news
    • Media Library
  • Work with us
    • Careers
    • Partnering

2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem

Nov 28, 2025 | 2025, Press Releases, Scientific

Dr. Samuele Cazzamalli, Head of Research at Philochem, will be awarded the Industrial Science Award 2026 from the Swiss Chemical Society. His research has focused on the discovery of novel tumor-targeting diagnostic and therapeutic agents through the use of...

The Board of Directors approves the financial position for the third quarter of 2025

Nov 11, 2025 | 2025, Investors, Press Releases

more details

Il Consiglio di Amministrazione approva la Posizione Finanziaria Netta relativa al terzo trimestre 2025

Nov 11, 2025 | 2025, Investors, Press Releases

more details

Il Consiglio di Amministrazione Approva la Relazione Finanziaria Semestrale al 30 giugno 2025 (Price sensitive)

Sep 23, 2025 | 2025, Investors, Press Releases

more details

The Board of Directors Approves the Half-Yearly Financial Report at 30 June 2025 (Price sensitive) – Courtesy English Translation

Sep 23, 2025 | 2025, Investors, Press Releases

more details

Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties

Aug 18, 2025 | 2025, Investors, Press Releases

For more details
« Older Entries
Next Entries »

Recent Posts

  • Philogen is pleased to invite you to an upcoming webinar on September 25, 2026, at 14:00 GMT | 15:00 CET.
  • Il Consiglio di Amministrazione Approva la Relazione Finanziaria Semestrale al 30 giugno 2026 (Price sensitive)
  • The Board of Directors Approves the Half-Yearly Financial Report at 30 June 2026 (Price sensitive) – Courtesy English Translation
  • Updated Phase III PIVOTAL Results for Nidlegy™ Published in the Journal of Clinical Oncology
  • Nidlegy™ Marketing Authorization Application Resubmitted to EMA

Recent Comments

    Legal

    Privacy Policy

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it